Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET-EBV in MS
2025-522140-40-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Tenofovir alafenamide add-on with Placebo add-on (2 arms). Primary endpoint: Change in cerebrospinal fluid neurofilament light chain. Planned start Aug 2025; status: authorised.
02
Drugs
tenofovir alafenamide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2025-522140-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522140-40-00.